Strengths

● Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 63% by 2026.

● The company's profit outlook over the next few years is a strong asset.

● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.

● Thanks to a sound financial situation, the firm has significant leeway for investment.

● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

● For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.


Weaknesses

● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 111.05 times its estimated earnings per share for the ongoing year.

● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

● The average consensus view of analysts covering the stock has deteriorated over the past four months.

● Over the past twelve months, analysts' consensus has been significantly revised downwards.

● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.